Press Releases Year None2020201920182017 Turning Point Therapeutics Names Heather Adams as Vice President of Human Resources Jul 27, 2020 Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer Jul 13, 2020 Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China Jul 07, 2020 Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models Jun 22, 2020 Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare Conference Webcast Jun 01, 2020 Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046 May 29, 2020 Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock May 27, 2020 Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock May 18, 2020 Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock May 18, 2020 Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response May 12, 2020 Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 21
Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer Jul 13, 2020
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China Jul 07, 2020
Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models Jun 22, 2020
Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare Conference Webcast Jun 01, 2020
Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046 May 29, 2020
Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock May 27, 2020
Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock May 18, 2020
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response May 12, 2020
